Impact of a Proprietary Standardized Olive Fruit Extract (SOFE) on Cardio-Ankle Vascular Index, Visual Analog Scale and C-Reactive Protein Assessments in Subjects with Arterial Stiffness Risk

Drugs in R and D

Volumn 16, Issue 4, 2016, Pages 355-368

  Pais, Pilar ^a   Villar, Agustin ^a   Rull, Santiago ^a  

^a Euromed   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYTYROSOL; IRON; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIVE OIL; PHENOL DERIVATIVE; PHOSPHORUS; PLACEBO; PLANT EXTRACT; STANDARDIZED OLIVE FRUIT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELASTICITY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE; ANKLE BRACHIAL INDEX; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FRUIT; METABOLISM; MIDDLE AGED; OLIVE TREE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANKLE BRACHIAL INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRUIT; HUMANS; MIDDLE AGED; OLEA; PLANT EXTRACTS; RISK FACTORS; TRIGLYCERIDES; VASCULAR STIFFNESS; VISUAL ANALOG SCALE;

EID: 84992699356     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-016-0147-7     Document Type: Article

References (56)

1. Tabernero M, Sarriá B, Largo C, et al. Comparative evaluation of the metabolic effects of hydroxytyrosol and its lipophilic derivatives (hydroxytyrosyl acetate and ethyl hydroxytyrosyl ether) in hypercholesterolemic rats. Food Funct. 2014;5:1556–63.
2. Covas MI, Nyyssönen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006;145:333–41.
3. Verhoeven V, der Auwera Van A, Gaal Van L, et al. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2015;15:52.
4. Dubick MA, Omaye ST. Evidence for grape, wine and tea polyphenols as modulators of atherosclerosis and ischemic heart disease in humans. J Nutraceut Funct Med Foods. 2001;3:67–93.
5. Nardini M, Natella F, Scaccini C. Role of dietary polyphenols in platelet aggregation. A review of the supplementation studies. Platelets. 2007;18:224–43.
6. Moreno-Luna R, Munoz-Hernandez R, Miranda ML, et al. Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. Am J Hypertens. 2012;25:1299–304.
7. Visioli F, Bernardini E. Extra virgin olive oil’s polyphenols: biological activities. Curr Pharm Des. 2011;17:786–804.
8. Visioli F, Bellomo G, Galli C. Free radical-scavenging properties of olive oil polyphenols. Biochem Biophys Res Commun. 1998;247:60–4.
9. Visioli F, Galli C. The effect of minor constituents of olive oil on cardiovascular disease; new findings. Nutr Rev. 1998;56:142–7.
10. Visioli F, Galli C. Antiatherogenic components of olive oil. Curr Atheroscler Rep. 2001;3:64–7.
11. Visioli F, Galli C, Bornet F, et al. Olive oil phenolics are dose-dependently absorbed in humans. FEBS Lett. 2000;468:159–60.
12. Wiseman SA, Mathot JN, de Fouw NJ, et al. Dietary non-tocopherol antioxidants present in extra virgin olive oil increase the resistance of low density lipoproteins to oxidation in rabbits. Atherosclerosis. 1996;120:15–23.
13. Caruso D, Berra B, Giavarini F, et al. Effect of virgin olive oil phenolic compounds on in vitro oxidation of human low density lipoproteins. Nutr Metab Cardiovasc Dis. 1999;9:102–7.
14. Coni E, Di Benedetto R, Di Pasquale M, et al. Protective effect of oleuropein, an olive oil biophenol, on low density lipoprotein oxidizability in rabbits. Lipids. 2000;35:45–54.
15. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2:270–8.
16. Angerer P, Kothny W, Störk S, et al. Effect of dietary supplementation with v-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res. 2002;54:183–90.
17. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (cavi) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011;18:924–38.
18. Kinouchi K, Ichihara A, Sakoda M, et al. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res. 2010;33:304–12.
19. Izuhara M, Shioji K, Kadota S, et al. Relationship of cardioankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J. 2008;72:1762–7.
20. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res. 2008;31:1347–55.
21. Kubozono T, Miyata M, Ueyama K, et al. Acute and chronic effects of smoking on arterial stiffness. Circ J. 2011;75:698–702.
22. Park HE, Choi SY, Kim HS, et al. Epicardial fat reflects arterial stiffness: assessment using 256 slice multidetector coronary computed tomography and cardio-ankle vascular index. J Atheroscler Thromb. 2012;19:570–6.
23. Nakamura K, Tomaru T, Yamamura S, et al. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J. 2008;72:598–604.
24. Okura T, Watanabe S, Kurata M, et al. Relationship between cardio-ankle vascular index (cavi) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res. 2007;30:335–40.
25. Suzuki J, Sakakibara R, Tomaru T, et al. Stroke and cardio-ankle vascular stiffness index. J Stroke Cerebrovasc Dis. 2013;22:171–5.
26. Choi SY, Oh BH, Bae Park J, et al. Age-associated increase in arterial stiffness measured according to the cardio-ankle vascular index without blood pressure changes in healthy adults. J Atheroscler Thromb. 2013;20:911–23.
27. Miyoshi T, Doi M, Hirohata S, et al. Cardio-ankle vascular index is independently associated with the severity of coronary atherosclerosis and left ventricular function in patients with ischemic heart disease. J Atheroscler Thromb. 2010;17:249–58.
28. Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res. 2009;32:1004–8.
29. Sun CK. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. Integr Blood Press Control. 2013;6:27–38.
30. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13:227–36.
31. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol. 2004;31:1896–902.
32. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–5.
33. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8.
34. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281–8.
35. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
36. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
37. Passacquale G, Di Giosia P, Ferro A. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. Cardiovascular Res. 2016;109:9–23.
38. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.
39. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.
40. Hulley SB, Rosenman RH, Bawol RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383–9.
41. Conference Consensus. treatment of hypertriglyceridemia. JAMA. 1984;251:1196–200.
42. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. NIH Consensus Conference: triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505–10.
43. Patrick L, Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev. 2001;6:248–71.
44. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–90.
45. Migliori M, Panichi V, de la Torre R, et al. Anti-inflammatory effect of white wine in CKD patients and healthy volunteers. Blood Purif. 2015;39:218–23.
46. Yonei Y, Iwabayashi M, Fujioka N. Evaluation of effects of cassis (Ribes nigrum L.) juice on human vascular function and gene expression using a microarray system. Anti-Aging Med. 2009;6:22–31.
47. EFSA Panel on Dietetic Products. EFSA Panel on dietetic products. Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage. EFSA J. 2011;9:2033.
48. Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr. 2005;81:292–7.
49. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10–5.
50. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434–9.
51. Kadota K, Takamura N, Aoyagi K, et al. Availability of cardioankle vascular index (CAVI) as a screening tool for atherosclerosis. Circ J. 2008;72:304–8.
52. Namekata T, Suzuki K, Ishizuka N, et al. Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study. BMC Cardiovasc Disord. 2011;11:51.
53. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 2000;71:1062–76.
54. García-Lafuente A, Guillamón E, Villares A, et al. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 2009;58:537–52.
55. Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:539–45.
56. Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb. 2009;16:621–6.